Kornimate/medical-research-clean huggingface dataset:
combination chemotherapy in patients with newly diagnosed bpdcn

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Summary: patients with suspected bpdcn and meeting eligibility criteria will be enrolled in the study. first, bpdcn diagnosis will be confirmed by anatomic pathology (dr petrella t, montreal) and cytologic plus immunophenotyping analysis (pr garnache ottou f, umr1098 besancon). patients will then receive three 21 days cycles of a combination of chemotherapy (ida/metho/l-asp/dex), followed by an evaluation. patients with complete response (cr) or complete response with incomplete bone marrow recovery (cri) will undergo an allo- or auto-sct and those who are not eligible to the transplantation will have successive 28 days cycles of chemotherapy (metho/l-asp/dex). patients who did not respond to the treatment will be treated by physicians. all patients will be followed for 24 months.


Eligibility criteria:
inclusion criteria: * newly diagnosed bpdcn established by a blood or bone marrow immunophenotypic diagnosis by flow cytometric and/or by the anatomic pathology study of a skin biopsy using validated diagnostic criteria (swerdlow sh ce et al., world health organisation classification of tumors, 2008; garnache-ottou et al., 2009; angelot et al., 2012; julia et al., 2014) or patients with confirmed isolated skin lesion. * 18 years of age or older * no prior cytotoxic therapy except \<2 week of corticosteroids or hydroxyurea * ecog ≤2 * written informed consent * affiliation to the french social security scheme exclusion criteria: * cardiac contra-indication to anthracyclines: cardiac dysfunction events (nyha grade 3 or 4 and/or lvef\<50%) * hepatocellular abnormalities except if considered related to the bpdcn: 1. asat (sgot) and/or alat (sgpt) \> 5 x uln 2. total bilirubin ≥ 2.5 x uln * creatinine level \>1.5x uln or creatinine clearance (mdrd)\<50 ml/mn * prior thrombotic event * active hepatitis b or c virus infection * hiv positive * serious medical or psychiatric illness that could interfere with the completion of treatment * known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent. * pregnant and lactating female patients * patients diagnosed with or treated for another malignancy within 2 years before study enrollment or with residual disease (basal cell carcinoma or cervical carcinoma in situ patients may be enrolled if they have undergone complete resection)
rut vs. molecular testing for h. pylori

Conditions: H.Pylori Infection

Summary: the rapid urease test (rut) is frequently performed for diagnosis of helicobacter pylori infection in clinical practice. the rut is a simple and inexpensive method that utilizes a commercial kit containing urea and a ph indicator such as phenol red. in the presence of h. pylori urease, urea is hydrolyzed to ammonia, which raises the ph of the medium, and changes the color of the kit from yellow to magenta or pink. the sensitivity and specificity of rut were reported to range between 80-100% and 97-99%, respectively. when endoscopy is performed, rut is known as the first-line method used for h. pylori diagnosis. however, rut is an indirect test method, and has the disadvantage of causing false positivity due to other urease-producing bacteria. to date, gold standards for h. pylori diagnosis are culture and histological examination because h. pylori is a rather fastidious and slow-growing bacterium, antimicrobial susceptibility testing using culture methods is time-consuming (10-14 days) and requires specific expertise. recently, dual priming oligonucleotide (dpo)-based multiplex polymerase chain reaction (pcr) was developed to diagnose h. pylori infection. moreover, molecular testing can identify point mutations related to clarithromycin resistance. it can be performed in a standard thermocycler and takes only 4 h to complete. the concordance rate between conventional clarithromycin susceptibility testing and dpo-pcr was excellent up to 95%. however, there was no comparison study between rut and molecular testing for h. pylori diagnosis.

the investigators aim to compare the diagnostic accuracy of the rut and molecular testing, and identify clinical factors associated with the discordant results between the two methods.

Eligibility criteria:
inclusion criteria: * gastroscopy can be performed * h. pylori test and pathological analysis can be performed exclusion criteria: * age \ 80 years * anemia (serum hemoglobin level \< 10 g/dl) * severe systemic disease * advanced chronic liver disease * use of certain medications, including proton pump inhibitors, h2- receptor antagonists, or antibiotics * history of h. pylori eradication * drug allergy to antibiotics * history of gastric surgery * recent history of upper gastrointestinal bleeding
green tea effect on anthropometric, oxidation and inflammation parameters in physically active vs. sedentary elders

Conditions: Aging

Summary: the purpose of this study is to evaluate the beneficial effects of a long term (12 weeks) green tea drinking on plasma, erythrocytes and saliva oxidative stress biomarkers and antioxidant capacity, as well as on cardiometabolic risk factors: anthropometric, inflammation and metabolic parameters in a healthy aging men and women.

a prospective, crossover trial in which every individual served its own control. all subjects undergo a four weeks washout period, during which they briefed to avoid tea drinking and antioxidant supplements until the end of the study. at the end of the washout period, blood and saliva samples is collected after 12 hours of night fast. subsequently, all subjects receive the maltodextrin containing placebo "tea bags". the subjects instructed to brew the placebo sachets for five minute in 240 ml boiling water without stirring and to drink 4 cups per day for 12 weeks period (placebo period). after the placebo period, fasting samples collected once more and the subjects receive the green tea bags. preparation and drinking instructions are the same as the placebo drink. at the end of the 12 weeks, green tea drinking, fasting blood and saliva samples drawn for the third time. during the study, every 4 weeks the subjects get additional placebo or green tea bags. assessment of nutritional consumption of macronutrients and antioxidants using a food diary, physical activity lifestyle as well as weight, body fat and circumference measurements is made at the beginning, middle and end of the study.

Eligibility criteria:
inclusion criteria: * healthy men and women * age: 60-76 years * able to understand the meaning of informed consent procedure and willing to consent exclusion criteria: * any active disease state * unstable chronic disease (diabetes, vascular, renal)

Keywords: green tea, aging, oxidation, anthropometrics.
study with lu af87908 in healthy participants and participants with alzheimer's disease

Conditions: Healthy; Alzheimer Disease

Summary: the purpose of this study is to investigate the safety of a single dose of lu af87908, how well it is tolerated and what the body does to the drug in healthy participants and participants with alzheimer's disease.

the study will be divided into three parts: part a, part b and part c. part a consists of up to 6 sequential cohorts (cohorts a1 to a6): -cohorts a1 to a6: 8 healthy participants per cohort (aiming for an equal number of men and women): 6 randomized to lu af87908 and 2 randomized to placebo. part b consists of up to 3 sequential cohorts (cohorts b1 to b3): -cohorts b1 to b3: 4 japanese and 4 chinese healthy participants per cohort: 6 participants randomized to lu af87908 and 2 participants randomized to placebo. part c consists of 2 sequential cohorts (cohorts c1 and c4): -cohort c1 will consist of 6 participants with alzheimer's disease with 3:1 randomization scheme for active: placebo. cohort c4 will consist of up to 8 participants. cohort c4 participants will be randomized based on the randomization scheme from cohort c1.

Eligibility criteria:
inclusion criteria healthy participants: -men and women ≥18 and ≤65 years of age with a body mass index (bmi) ≥18 and ≤32 kilograms (kg)/square meter (m\^2) and a minimum weight of 50 kg. participants with alzheimer's disease: * men and women with a clinical diagnosis of alzheimer's disease, stages 3-4 according to the fda guidelines. * mini-mental state examination (mmse) of 15-30. * clinical dementia scale (cdr) global score up to and including 2.0. * confirmed or determined (via amyloid positron emission tomography \[pet\] scan) to be amyloid positive. * if on fda approved alzheimer's disease medication, the treatment has been stable for 4 months prior to day 1. -≥50 years of age. * bmi ≥18 and ≤40 kg/m\^2 and a minimum weight of 50 kg. exclusion criteria: * clinically relevant structural brain abnormality as assessed using magnetic resonance imaging (mri). * any past or current treatment with an anti-abeta or anti-tau active vaccine. * any past or current treatment with a monoclonal anti-tau antibody or a tau anti-sense oligomer within the last 6 months. * treatment with covid-19, influenza or pneumonia vaccine within the last 30 days prior to dosing of investigational medicinal product (imp). other eligibility criteria may apply.
study to evaluate the efficacy and safety of p-3073 nail solution in the treatment of nails affected by psoriasis

Conditions: Nail Psoriasis

Summary: the purpose of this study is to confirm the clinical efficacy and the safety of p-3073 in patients affected by isolated psoriatic nail(s) and/or those with psoriatic nails and concomitant mild to moderate plaque psoriasis.


Eligibility criteria:
inclusion criteria: * written informed consent before starting any study related procedures * patients aged 18 to 80 years old of any race. * males or females. * patients with mild to moderate psoriastic fingernail(s) defined as fingernail/s with matrix psoriasis napsi score and/or bed psoriasis napsi score ≥ 1 and ≤ 3 at baseline. * in case of skin involvement, patients with established clinical diagnosis of mild-to-moderate psoriasis (bsa involvement ≤ 8% or pasi ≤ 10) exclusion criteria: * woman who is pregnant, nursing an infant, or planning a pregnancy during the study period. * use of any systemic treatment for psoriasis during the last six months before the screening visit. * use of photochemotherapy or other forms of radiotherapy during the last four weeks before the screening visit. * positive mycology findings * systemic use of immunosuppressives, chemotherapy and corticosteroids during last three months before the screening visit. * consumption of vitamin d or its analogues during the last three months. * history of hypercalcaemia or hypercalciuria. * hiv infection or any other immunodeficiency. * alcohol or substance abuse. * patients with history of allergic reactions to calcipotriol or its excipients.

Keywords: nail psoriasis
a study to evaluate the effects of sharpened romberg testing (srt) in healthy subjects

Conditions: Hypocapnia; Balance; Distorted

Summary: this research study is being done to evaluate the effectiveness of using the sharpened romberg test to screen for impaired postural control in patients with impaired or altered breathing patterns.

the effects of hypocapnia on the postural system have not previously been adequately investigated. the specific aim of this study is to evaluate the effects of hypocapnia on postural standing balance using the sharpened romberg test (srt). there is very little research in this area, even though there is significant clinical relevance, ranging from individuals with conditions affecting ventilation (respiratory conditions, cardiac conditions, concussions, medications, post-surgical states requiring ventilatory support etc). the design of the experiment consists of testing healthy subjects and measuring their standing balance with srt before and after they deliberately lower their carbon dioxide levels by increased ventilation over 2min. end-tidal co2 (etco2) will be used to estimate the blood carbon dioxide level during the experimental procedures. etco2 will be measured using the masimo, emma capnometer device. the device is a measurement tool that reads the end tidal carbon dioxide level on its display. the results will then be compared to the normal pre-hypocapnic srt to assess how hypocapnia affects standing balance.

Eligibility criteria:
inclusion criteria: - research subject conditions that may result in alterations of ventilatory control (capnic status) and balance will be specifically reviewed as criteria for participation. exclusion criteria: * current pregnancy in women, alcohol use within the past 3 days prior to the experiment, history of balance problems (e.g., vertigo, neuropathy, central or peripheral vestibular disorders), and musculoskeletal disorders affecting the ability to perform a srt in participants. * patients currently taking carbonic anhydrase inhibitors, opioids, benzodiazepines, hypnotics, first-generation h1 antihistamines, amphetamines, and first-generation antipsychotics. * patients with a history of insomnia, sleep apnea, circadian rhythm disturbances, narcolepsy, movement disorders, chronic low blood pressure, fainting spells, multiple concussions, seizure disorders, migraines, severe headaches and panic attacks. * if the patient took medications known to cause prolonged qtc interval and other cardiac arrhythmias, the researchers will exclude the patient from the study.

Keywords: hypocapnia balance
aki risk factors analysis after intentional hypotensive anesthesia

Conditions: Acute Kidney Injury (Nontraumatic); Hypotension Drug-Induced

Summary: this project investigates intentionally hypotensive management such as ntg (nitroglycerin) or ntg+trandate during general anesthesia in patients undergoing orthognathic surgery. throughout the entire surgical procedure, blood biochemical and urine monitoring will be conducted. serum creatinine (cr) levels, urine analysis, and perioperative monitoring will be utilized as indicators for assessing renal function during the surgery. the objective is to assess its potential renal injury and identify early risk factors for acute kidney injury (aki). timely recognition of these factors will allow for the implementation of appropriate intervention strategies, aiding in the prevention of postoperative acute kidney injury. this approach contributes to achieving the goals of enhanced recovery after surgery (eras) for surgical patients, promoting faster postoperative recovery.

orthognathic surgery is currently a common procedure in oral and maxillofacial surgery. the facial region is composed of a complex and dense vascular network, requiring precise, accurate, and delicate surgical techniques on both hard and soft tissues. during intraoral procedures, the surgical field may be limited, making the management of surgical bleeding challenging. controlled hypotension or hypotensive anesthesia is often employed during major maxillofacial surgeries to optimize conditions. lowering blood pressure is advantageous as it helps reduce overall blood loss and improves the surgeon's visibility. therefore, maintaining stable blood pressure within the ideal range during the surgical process is a critical anesthesia objective. this research emphasizes the prevention of acute kidney injury (aki) in patients undergoing orthognathic surgery with intentional hypotension during general anesthesia. the goal is to detect the potential renal damage at an early stages, before a significant decline in kidney function occurs, thereby reducing the likelihood of acute kidney injury.

Eligibility criteria:
inclusion criteria: * america society anesthesiologist classification class i to ii patients undergoing oro-maxillo-facial surgery * unlimited mouth opening exclusion criteria: * patients with arthritis with limited mouth opening * persistent liver dysfunction * chronic renal insufficiency * body mass index ≧35 kg/m2. * past history of malignant hyperthermia or personal or family history * diabetes with insulin treatment * essential hypertension without controlled

Keywords: acute kidney injury orthognathic surgery general anesthesia prospective analysis intentional hypotension
screening for malnutrition in obese patients

Conditions: Overweight and Obese Adults; Malnutrition or Risk of Malnutrition

Summary: more than half of the dutch population is overweight or obese, which is associated with an increased risk of covid-19 and worse outcomes during a covid-19 infection. in addition, malnutrition and loss of muscle mass are often reported with covid-19, as well as with cancer and other diseases. malnutrition and overweight or obesity can coexist, even within the same individual. it is still unclear which mechanisms contribute to the worse outcomes of covid-19 and other diseases in case of overweight, malnutrition, and a combination of both. the aim of this study is to identify which parameters are associated with worse disease outcomes through literature research and database research (covid-19 and cancer, more than 150.000 participants). in addition, a clinical study will be conducted aiming to develop a simple screening tool for the recognition of the coexistence of malnutrition and overweight or obesity in clinical practice.

overweight and malnutrition are both common and have a significant societal impact as well as a negative effect on healthcare. they can also coexist, and may potentially reinforce each other. how the combination of both influences the course of covid-19 and other diseases is still largely unknown. there is no simple set of parameters yet available to screen for the simultaneous occurrence of overweight and malnutrition. this project has the following objectives: * to evaluate the nutritional status (malnutrition, overweight, and the combination of both) and the (dietary) treatment of patients with covid-19 in primary care (wp1). * to assess the influence of various parameters of malnutrition and overweight and their effects on the outcomes of covid-19 and cancer based on literature and data from existing dutch cohorts (wp2 and wp3). based on this, to develop a screening tool for malnutrition in overweight; (wp4). - dissemination of the results (wp5).

Eligibility criteria:
inclusion criteria: * age 18 years or older * overweight (bmi of 25 kg/m² or higher) exclusion criteria: * physically or mentally unable to participate. * severe cognitive disorder or severe emotional instability, as assessed by the attending nurse or physician. * insufficient proficiency in the dutch language to express themselves properly and no interpreter or assistant to help. * patient resides in a nursing or care home.

Keywords: overweight obesity malnutrition
metformin in gestational diabetes mellitus

Conditions: Diabetes, Gestational; Insulin Resistance

Summary: gestational diabetes (gdm) is a condition that manifests as high blood sugar levels (hyperglycemia) during pregnancy in previously healthy women. it develops as a result of increased maternal body's resistance to insulin - a major hormone that allows for utilisation of glucose (sugar taken in with food) within cells. it was found out that gdm occurs more frequently in overweight women but also in women with a history of certain conditions such as polycystic ovary syndrome (pcos). usually, gdm disappears after pregnancy is completed but it is associated with some serious hazards for women and her unborn child, if untreated properly. diet is a first-choice treatment but sometimes insulin therapy must be initiated if keeping a diet alone is not enough to maintain blood sugar within recommended values. insulin therapy is effective but it requires several injections during each day and insulin is a strong acting hypoglycemic agent that may induce rapid falls in blood sugar, also dangerous for mother and unborn child. in the investigators study, the investigators would like to investigate if metformin that is a commonly used hypoglycemic drug can be effectively used for gdm treatment. metformin has been used successfully for a long time to treat type 2 diabetes mellitus and pcos and, according to current data, it is not dangerous neither for mother nor for baby when used during gestation.


Eligibility criteria:
inclusion criteria: * diabetes diagnosed during pregnancy * single pregnancy * ineffective diet therapy exclusion criteria: * pregestational diabetes * fetal malformation * multiple pregnancy * contraindications to metformin therapy (liver or kidney disease)

Keywords: gestational diabetes birth weight fetal growth insulin resistance oxidative stress inflammatory reaction fetal development
laser therapy on tmj disorders after head and neck cancer.

Conditions: Temporomandibular Joint Disorders

Summary: temporomandibular disorder (tmd) is a term describing musculoskeletal conditions of the face, jaw and temporal regions. tmd is frequently associated with pain and/or dysfunction such as impaired jaw function, pain in the temporomandibular joint (tmj), muscles and/or related structures, and associated headaches. the aetiology of tmd is multifactorial and complex.

it is known that one cause of tmd symptom development is treatment for head and neck cancer (hnc). the main treatment modalities for hnc include radiotherapy (rt) with or without chemotherapy and surgical intervention, either as a single therapy or a combination therapy. in the head and neck region, the anatomical structures are necessary for essential functions such as speech, swallowing, breathing, smell, and taste. the treatment of head and neck tumours may frequently impair some of these functions, which may result in pain, oral dysfunction, and impaired health-related quality of life. high intensity laser therapy (hilt) is a non-invasive and painless treatment method. the latest studies have reported the beneficial effects of neodymium-doped yttrium aluminum garnet (nd: yag) laser therapy in patients with pain. the advantage of hilt over low level laser therapy (lllt) is that hilt is able to penetrate and stimulate wider and/or deeper areas; thus, considerably more energy may be transmitted to tissue during hilt therapy compared to lllt.

Eligibility criteria:
inclusion criteria: 1. patients with temporomandibular joint disorders (myofascial pain, trismus and limitation of rom) after head and neck cancer, patients will be diagnosed by an experienced oral and maxillofacial surgeon. 2. patients with 20 to 60 years old. 3. 6 months after ending radiotherapy. exclusion criteria: 1. patients with implants. 2. current metastasis. 3. continuing radiotherapy. 4. pregnant females. 5. sensitivity to phototherapy. 6. bells palsy. 7. subjects with disk displacement, arthralgia or osteoarthritis at tmj. 8. subjects who received analgesics or antidepressants.

Keywords: high intensity laser therapy temporomandibular joint disorders head and neck cancer